Previous 10 | Next 10 |
Sesen Bio (NASDAQ: SESN ) has completed a successful Type B Pre-BLA meeting regarding the approval path for Vicinium for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). More news on: Sesen Bio, Inc., Healthcare ...
FDA Recommends Accelerated Approval Pathway FDA Indicated No Additional Clinical Trials Necessary for BLA Submission Company Expects to Initiate Submission of the BLA in 4Q 2019 Under Rolling Review Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing target...
Sesen Bio (NASDAQ: SESN ) will host a conference call on June 10 to provide regulatory update on Pre-BLA meeting for Vicinium. More news on: Sesen Bio, Inc., Read more ...
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr. Thomas Cannell, President and CEO will host a conference call on Monday, June 10, 2019 at 8:00 a.m. E...
May 29, 2019 Palm Beach, FL –May 29, 2019 – Cellulite affects 85% to 90% of all women worldwide and was first described nearly 100 years ago… and has been the bane of women (and men) ever since. But to find a ‘cure’ or effective ‘sol...
You don’t make money when you buy stocks. And you don’t make money when you sell stocks. You make money by waiting. - The Dhando Investor (Mohnish Pabrai) As you probably know, I'm mostly focused on small- and mid-cap ("SMID") bioscience equities. And my "sweet spots" are g...
Gainers: CIRCOR International, Inc. (NYSE: CIR ) +41% . JMU Limited (NASDAQ: JMU ) +39% . Westwater Resources, Inc. (NASDAQ: WWR ) +21% . Biocept, Inc. (NASDAQ: BIOC ) +22% . Sesen Bio, Inc. (NASDAQ: SESN ) +21% . OncoSec Medical Incorporated (NASDAQ: ONCS ) +20% . Dycom Indust...
CIRCOR (NYSE: CIR ) +51% on Crane buyout offer . More news on: CIRCOR International, Inc., JMU Limited, Biocept, Inc., Stocks on the move, Read more ...
Sesen Bio (NASDAQ: SESN ) announces that it has completed its meeting with the FDA regarding the Analytical Comparability Plan to ensure the consistency of manufacturing quality between its Winnipeg, Manitoba site, which made lead candidate Vicinium for its Phase 2 and 3 clinical trials, a...
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company has completed its Type C CMC meeting and has reached agreement with the U.S. Food and Drug Administration (FDA...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...